1-4 of 4
Annabell F. Leske
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer

Tina C. Lavranos, Donna Beaumont, Daniel Inglis, Michaela Scherer, Chloe Hawkins, Annabell F. Leske, Gabriel Kremmidiotis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B92.
https://doi.org/10.1158/1535-7163.TARG-15-B92
Published: 01 December 2015
View article titled, Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer
Journal Articles

Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors

Tina C. Lavranos, Daniel Inglis, Donna Beaumont, Annabell F. Leske, Chloe Hawkins, Michaela Scherer, Charles Hart, Jessica Sun, Brian Elenbaas, Gabriel Kremmidiotis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B174.
https://doi.org/10.1158/1535-7163.TARG-15-B174
Published: 01 December 2015
View article titled, Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors
Journal Articles

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival.

Daniel J. Inglis, Tina C. Lavranos, Donna M. Beaumont, Annabell F. Leske, Chloe K. Brown, Gabriel Kremmidiotis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B67.
https://doi.org/10.1158/1535-7163.TARG-13-B67
Published: 01 November 2013
View article titled, Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival.
Journal Articles

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

Gabriel Kremmidiotis, Annabell F. Leske, Tina C. Lavranos, Donna Beaumont, Jelena Gasic, Allison Hall, Michael O'Callaghan, Clayton A. Matthews, Bernard Flynn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1562–1573.
https://doi.org/10.1158/1535-7163.MCT-09-0815
Published: 09 June 2010
View article titled, BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
Open the PDF for BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy in another window
Includes: Supplementary data